Geneva Capital Management LLC Purchases 2,241 Shares of STAAR Surgical (NASDAQ:STAA)

Geneva Capital Management LLC increased its position in shares of STAAR Surgical (NASDAQ:STAA) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 695,415 shares of the medical instruments supplier’s stock after purchasing an additional 2,241 shares during the period. Geneva Capital Management LLC’s holdings in STAAR Surgical were worth $25,835,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Texas Permanent School Fund Corp increased its stake in STAAR Surgical by 1.0% in the 1st quarter. Texas Permanent School Fund Corp now owns 42,577 shares of the medical instruments supplier’s stock worth $1,630,000 after buying an additional 407 shares in the last quarter. Swiss National Bank raised its stake in STAAR Surgical by 0.8% during the 1st quarter. Swiss National Bank now owns 77,100 shares of the medical instruments supplier’s stock valued at $2,951,000 after purchasing an additional 600 shares during the period. Russell Investments Group Ltd. lifted its holdings in STAAR Surgical by 1.5% in the 1st quarter. Russell Investments Group Ltd. now owns 36,931 shares of the medical instruments supplier’s stock worth $1,406,000 after purchasing an additional 555 shares in the last quarter. ProShare Advisors LLC boosted its stake in STAAR Surgical by 8.4% in the 1st quarter. ProShare Advisors LLC now owns 9,892 shares of the medical instruments supplier’s stock worth $379,000 after purchasing an additional 763 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its holdings in STAAR Surgical by 11.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,441 shares of the medical instruments supplier’s stock valued at $591,000 after buying an additional 1,560 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group reduced their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, August 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and an average price target of $43.33.

STAAR Surgical Stock Performance

Shares of NASDAQ STAA opened at $29.02 on Wednesday. The business’s 50 day moving average price is $31.52 and its 200-day moving average price is $37.62. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 65.95 and a beta of 0.61. STAAR Surgical has a fifty-two week low of $26.66 and a fifty-two week high of $52.68.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.